Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dense Breasts Clear all
Not listed Phase 2 Interventional

Capecitabine in Metastatic Breast and GI Cancers

NCT02595320
View directory record Official record
Conditions
Breast Cancer, Gastrointestinal Cancer
Interventions
Capecitabine
Drug
Lead sponsor
Qamar Khan
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
15
States / cities
Fairway, Kansas • Garden City, Kansas • Great Bend, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

NCT00861705
View directory record Official record
Conditions
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Bevacizumab, Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
448
States / cities
Jonesboro, Arkansas • Rogers, Arkansas • Berkeley, California + 309 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Full-Field Digital Mammography With Digital Breast Tomography for Screening Call-Back Rates

NCT01236781
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Screening Tomosynthesis, Diagnostic Tomosynthesis
Device
Lead sponsor
American College of Radiology
Other
Eligibility
25 Years and older · Female only
Enrollment
558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

NCT00546156
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Ian E. Krop, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Hooksett, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 22, 2026, 10:51 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts

NCT02042456
View directory record Official record
Conditions
Breast Cancer
Interventions
Digital Breast Tomosynthesis, Automated Whole Breast Ultrasound, Full Field Digital Mammography
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 22, 2026, 10:51 AM EDT
Completed No phase listed Observational

Delphinus SoftVue™ ROC Reader Study

NCT03972605
View directory record Official record
Conditions
Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
Interventions
Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 1 Interventional

Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer

NCT00107094
View directory record Official record
Conditions
Breast Cancer
Interventions
Abraxane
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2007 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

NCT02489448
View directory record Official record
Conditions
Breast Neoplasms
Interventions
MEDI4736
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 22, 2026, 10:51 AM EDT
Completed No phase listed Observational

A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.

NCT00816530
View directory record Official record
Conditions
Breast Cancer
Interventions
Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
Device
Lead sponsor
U-Systems, Inc.
Industry
Eligibility
25 Years and older · Female only
Enrollment
15,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Indio, California • Monterey, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 22, 2026, 10:51 AM EDT
Terminated Phase 2 Interventional Results available

Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer

NCT01194869
View directory record Official record
Conditions
Breast Cancer
Interventions
Sorafenib, Cisplatin, Paclitaxel
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 22, 2026, 10:51 AM EDT
Terminated Phase 3 Interventional Results available

Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue

NCT03199963
View directory record Official record
Conditions
Mammographic Breast Density
Interventions
4-OH tamoxifen, Placebo
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 22, 2026, 10:51 AM EDT
Completed No phase listed Observational

Delphinus SoftVue™ ROC Reader Study

NCT03698942
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

NCT00620373
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
969 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 22, 2026, 10:51 AM EDT
Not listed No phase listed Observational

A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue

NCT05268224
View directory record Official record
Conditions
Breast Cancer Screening
Interventions
Schirmer Strip
Diagnostic Test
Lead sponsor
Namida Lab
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Dual-energy (DE) Contrast-enhanced (CE) Digital Mammography

NCT02995980
View directory record Official record
Conditions
Breast Cancer
Interventions
Dual-Energy Contrast-Enhanced (DECE) mammography, digital mammography
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 22, 2026, 10:51 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

NCT02933489
View directory record Official record
Conditions
Asymptomatic
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Digital Tomosynthesis Mammography, Quality-of-Life Assessment, Questionnaire Administration
Diagnostic Test · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
40 Years to 75 Years · Female only
Enrollment
1,516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
67
States / cities
Gilbert, Arizona • Pasadena, California • Denver, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 22, 2026, 10:51 AM EDT
Completed No phase listed Observational

Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging

NCT01027767
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Dose Dense TC + Pegfilgrastim Support for Breast Cancer

NCT01671319
View directory record Official record
Conditions
Female Breast Cancer
Interventions
docetaxel + cyclophosphamide + pegfilgrastim
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 22, 2026, 10:51 AM EDT
Completed No phase listed Observational

Delphinus SoftVue Prospective Case Collection - ARM 2

NCT02977247
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Non-Interventional, Automated Whole Breast Ultrasound
Other · Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Los Angeles, California • Miami Beach, Florida • Savannah, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 22, 2026, 10:51 AM EDT
Recruiting Phase 2 Interventional

A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

NCT07768436
View directory record Official record
Conditions
Adenocarcinoma of the Breast, Breast Cancer, Triple Negative Breast Cancer
Interventions
CMF Regimen, Paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
70 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 10:51 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

NCT01498588
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast
Interventions
Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Early Phase 1 Interventional

Detection and/or Evaluation of Dense Breast Abnormalities Using Tomosynthesis and Digital Mammography

NCT00722059
View directory record Official record
Conditions
Breast Neoplasms, Breast Abnormalities
Interventions
Breast Tomosynthesis
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
30 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

NCT00270894
View directory record Official record
Conditions
Breast Neoplasm
Interventions
epirubicin, cyclophosphamide, docetaxel, trastuzumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
Miami, Florida • Augusta, Georgia • Macon, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 22, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer

NCT00232479
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, docetaxel and carboplatin in dose dense regimen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 22, 2026, 10:51 AM EDT